SEHK:1477Pharmaceuticals
Ocumension Therapeutics (SEHK:1477) Revenue Growth Tests Bullish Profitability Narratives
Ocumension Therapeutics (SEHK:1477) opened FY 2025 with first half revenue of C¥294.0 million and a basic EPS loss of C¥0.17, alongside trailing 12 month revenue of C¥804.4 million and a basic EPS loss of C¥0.20 that keeps the business in loss making territory. Over the last three reported half year periods, the company has seen revenue move from C¥167.6 million in 1H 2024 to C¥249.7 million in 2H 2024 and then to C¥294.0 million in 1H 2025. Basic EPS losses moved from C¥0.23 to C¥0.17 and...